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Biologics that neutralize speciﬁc cytokines have
improved outcomes for several immune-mediated
disorders but may also increase risks for particular
side effects. This article postulates potential immuno-
logic consequences of inhibiting components of the
IL-23/T-helper cell 17 pathway–the target of next-
generation biologics for treating psoriasis–based on
clinical phenotypes of inherent or acquired deﬁcien-
cies in this pathway. Generally, downstream deﬁcien-
cies (e.g., IL-17A, IL-17F) are associated with fewer
disorders compared with upstream deﬁciencies, sug-
gesting that selectively blocking downstream targets
may result in a narrower range of side effects.
However, safety of these speciﬁc inhibitions must be
established in long-term studies.
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INTRODUCTION
Imbalances in cytokine levels have been implicated in the
pathogenesis of a variety of diseases (O'Shea et al., 2002). For
disorders in which cytokines are upregulated, such as psoriasis
and rheumatoid arthritis, biologic agents that neutralize
speciﬁc cytokines have improved treatment outcomes while
decreasing side effects (Kim and Solomon, 2010; Focosi et al.,
2011). Such drugs act therapeutically by modulating abnormal
immune responses caused by aberrant cytokine levels. An
unintended consequence, however, is that these therapies
may also inhibit normal host defenses that utilize the targeted
cytokine (Kim and Solomon, 2010; Chu, 2013).
Clinical improvements observed in patients with psoriasis
and rheumatoid arthritis treated with tumor necrosis factor-α
inhibitors have inspired researchers to study novel cytokine
targets with the goal of maximizing therapeutic efﬁcacy while
minimizing side effects (Nwe et al., 2013). Targeting these
cytokines may alleviate safety concerns resulting from
upstream cytokine inhibition and inhibition at multiple
points in the inﬂammatory cascade (Bongartz et al., 2006;
Leombruno et al., 2009). As understanding of the patho-
genesis of inﬂammatory and immune-mediated diseases has
improved, cytokines involved in the IL-23/T-helper cell (Th)17
pathway have been identiﬁed as key modulators of adaptive
immune responses associated with the initiation, progression,
and maintenance phases of these diseases (Blauvelt, 2008;
Kellner, 2013; Qu et al., 2013). Therefore, there is a strong
rationale for targeting cytokines in this pathway (Figure 1a).
Because antimicrobial peptides partially triggered by the
IL-23/Th17 pathway are involved in mucocutaneous defense
against bacterial and fungal pathogens, therapeutic targeting
of this cytokine may increase susceptibility to these infections
(Waite and Skokos, 2012; Bedoya et al., 2013; Kellner, 2013).
Hence, this article will review the role of the IL-23/Th17
pathway in the pathogenesis of immune-mediated disorders
and explore potential immunologic consequences of inhibit-
ing members of this pathway. The principal method for
understanding the immunologic consequences of disrupting
the IL-23/Th17 pathway will be to examine clinical pheno-
types associated with pathway deﬁciencies, which may occur
because of genetic mutations affecting the production or
activation of a speciﬁc cytokine or its receptor or because
of the production of autoantibodies against endogenous
cytokines.
ROLE OF THE IL-23/TH17 PATHWAY IN THE
PATHOGENESIS OF PSORIASIS AND OTHER
IMMUNE-MEDIATED DISEASES
In patients with psoriasis, Th17 cells are elevated in cutaneous
lesions and blood, as are the messenger RNA and protein
levels of IL-23, IL-17A, IL-17F, IL-22, and IL-21 (Di Cesare
et al., 2009; Kagami et al., 2010; Michalak-Stoma et al., 2011;
Yilmaz et al., 2012; Nwe et al., 2013). These ﬁndings suggest
that Th17 cells and associated cytokines are important
pathogenic mediators of psoriasis (Hueber et al., 2010). The
IL-23/Th17 pathway model postulates that, in response to a
speciﬁc trigger, speciﬁc cells produce tumor necrosis factor-α,
IL-1β, IFN-α, and IL-6 in susceptible individuals (Lynde et al.,
2014). These cytokines stimulate myeloid dendritic cells to
produce IL-23, which promotes Th17 cell differentiation,
proliferation, and maintenance (Rizzo et al., 2011; Lynde
et al., 2014). Th17 cells migrate to the skin and become
activated via the signal transduction protein signal transducer
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Figure 1. Role of cytokines in psoriasis pathophysiology and immune defense against infections. (a) Pathophysiology of psoriasis, with indications for the relative
positions of key cytokines and their inhibitors. (b) Signaling pathways associated with speciﬁc increases in susceptibility to pathogens. HSV, herpes simplex virus;
NEMO, NF-kappaB essential modulator; STAT, signal transducer and activator of transcription; TIR, Toll-like receptor/IL-1 receptor; TNF-R, tumor necrosis factor
receptor; TYK, tyrosine kinase (Bustamante et al., 2008). Adapted from Bustamante et al., 2008, with permission from Elsevier.
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and activator of transcription 3 (STAT3) to produce IL-17A,
IL-17F, and IL-22, along with several chemokines. In addition,
IL-17-, IL-21-, and IL-22-producing CD8+ T cells have been
observed in psoriatic plaques and implicated in the patho-
genesis of psoriasis (Ortega et al., 2009; Res et al., 2010).
Together, these cytokines and chemokines drive chronic
inﬂammation associated with psoriatic lesion formation,
including keratinocyte activation and hyperproliferation.
Activated keratinocytes, in turn, produce many of the same
pro-inﬂammatory mediators that initiate the psoriasis cascade,
thereby creating a self-perpetuating cycle that leads to
persistence of psoriatic plaques (Di Cesare et al., 2009;
Harper et al., 2009; Gaffen, 2011; Girolomoni et al., 2012;
Nwe et al., 2013).
PHENOTYPIC PRESENTATION OF CYTOKINE OR
RECEPTOR DEFICIENCIES IN THE IL-23/TH17 PATHWAY
Several unique defects have been identiﬁed in genes that
encode for components of the IL-23/Th17 pathway. These
genetic mutations result in a number of rare, complex human
diseases associated with either cytokine or receptor deﬁcien-
cies or with autoantibody production. Common conse-
quences of these disorders are increased susceptibility to
pathogens due to changes in host defense. Table 1 provides a
summary of ﬁndings on human diseases associated with
defects in IL-23/Th17 function; descriptions of the phenotypic
presentations of these diseases follow.
Mendelian susceptibility to mycobacterial disease (MSMD)
Mendelian susceptibility to mycobacterial disease is a rare
syndrome with clinical symptoms resulting from infection
with mildly virulent bacteria (Fieschi et al., 2003 and 2004).
Although early descriptions of MSMD suggested that infection
susceptibility was usually limited to Mycobacterium and
Salmonella (Fieschi and Casanova, 2003; Fieschi et al., 2003
and 2004), more recent studies have shown that Candida
infections are not uncommon (~25% of patients), and
Klebsiella pneumonia infection, paracoccidioidomycosis,
and leishmaniasis have also been reported (Ouederni
et al., 2014; Ramirez-Alejo et al., 2014). Most Candida
infections in this population are isolated oropharyngeal
candidiasis, and risk of systemic infection is low (Fieschi
and Casanova, 2003; Ouederni et al., 2014). Patients with
MSMD do not exhibit increased susceptibility to common
viral pathogens, suggesting that their immune system is
not broadly compromised (Fieschi and Casanova, 2003).
However, the prognosis for MSMD varies, ranging from
complete recovery to premature mortality (Ramirez-Alejo
et al., 2014).
To date, nine mutations have been associated with MSMD;
the clinical phenotypes of MSMD can vary depending on the
nature of the underlying genetic mutation (Bustamante et al.,
2008; Ouederni et al., 2014; Ramirez-Alejo et al., 2014).
Mutations in IL12RB1, which encodes a common subunit of
the IL-12 and IL-23 receptor, can cause profound defects in
Table 1. Phenotypes of human immune–related disorders associated with the IL-23/Th17 pathway
Clinical presentation
Known defects associated
with disease Effects on IL-17, IL-23, and closely related cytokines
MSMD IL12RB1 mutation Impaired IFN-γ-mediated immunity
IL12B mutation
IFNGR1 mutation
STAT1 mutation
IL-12/23p40 deﬁciency
IL-12Rβ1 deﬁciency
Tuberculosis infection IL12RB1 mutation Reduced production of IFN-γ
Salmonella infection IL-23R deﬁciency Depletion of Th17 cells and IL-17A/F results in reduced immunoprotective effects
IL-12/23p40 deﬁciency
IL-12Rβ1 deﬁciency
CMC disease (associated
with C. albicans infection)
IL-17RA deﬁciency Reduced production of IL-17A, IL-17F, IL-22, and IFN-γ weaken
epithelial mucosal barriers
IL-17F deﬁciency
STAT1 GOF mutation
CARD9 mutation
Dectin-1 LOF mutation
APECED (APS-1) AIRE mutation High levels of autoantibodies to IL-17F, IL-22, and IL-17A
HIES (Job’s syndrome) STAT3 mutation (AD) Reduced differentiation of Th17 cells and production of IL-17A
DOCK8 mutation (AR)
Abbreviations: AD, autosomal dominant; APECED, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome; APS-1, autoimmune
polyendocrinopathy syndrome type 1; AR, autosomal recessive; CMC, chronic mucocutaneous candidiasis; GOF, gain-of-function; HIES, hyper-IgE
syndrome; LOF, loss-of-function; MSMD, Mendelian susceptibility to mycobacterial disease; Th, T-helper cell.
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IL-12 and IL-23 signaling (van de Vosse et al., 2013) and are
the most common cause of MSMD (Bustamante et al., 2008;
Ouederni et al., 2014). Patients with IL-12Rβ1 or IL-12/23p40
deﬁciencies are more susceptible to salmonellosis and mild
forms of candidiasis compared with patients with MSMD
caused by other mutations (Bustamante et al., 2008; Ouederni
et al., 2014). IFNGR1, IFNGR2, and STAT1 mutations directly
affect IFN-γ-mediated immune responses, and the level of
impairment in IFN-γ function is correlated with clinical
phenotype (i.e., patients with only partially impaired IFN-γ
responses have milder disease; Bustamante et al., 2008;
Boisson-Dupuis et al., 2012). The STAT1 mutations observed
in patients with MSMD are autosomal-dominant loss of
function and are associated with generally mild disease
(Boisson-Dupuis et al., 2012).
Tuberculosis
Mutations in IL12RB1 are also associated with increased
susceptibility to tuberculosis in humans (Altare et al., 1998;
Akahoshi et al., 2003; Al-Muhsen and Casanova, 2008; de
Beaucoudrey et al., 2010). It has been hypothesized that these
IL12RB1 polymorphisms may reduce receptor responsiveness
to IL-12 (and possibly IL-23), thereby disrupting IFN-γ-
mediated immunity (Akahoshi et al., 2003). Animal models
have also shown that TLR2-deﬁcient mice infected with M.
tuberculosis TLR2 have signiﬁcantly decreased Th17 cell
counts, IL-17 expression, and IL-23p19 expression (Teixeira-
Coelho et al., 2011). Similarly, polymorphisms in TLR2 and
TLR2-signaling molecules have been associated with
increased susceptibility to tuberculosis infection in humans
(Teixeira-Coelho et al., 2011). Observed IL-17A deﬁciencies
are probably of limited importance in host defense against
tuberculosis infection, as IL-22 has been shown to be the key
Th17 effector cytokine in pulmonary host defense mechan-
isms (Aujla et al., 2008), and depletion of IL-17A-producing
CD4+ T cells has been shown to have little to no effect on
disease progression during primary M. tuberculosis infection
(Khader et al., 2005).
Salmonella
Nontyphoidal Salmonella (NTS) infections can cause localized,
albeit potentially severe, gastroenteritis in immunocompetent
individuals. However, when immunocompromised indivi-
duals are exposed to NTS, the pathogen can spread beyond
the intestines to the bloodstream, resulting in a life-threatening
condition known as NTS bacteremia (Raffatellu et al., 2008;
Godinez et al., 2011). Studies in humans have linked
IL-12/IL-23-component deﬁciencies to increased susceptibi-
lity to severe extra-intestinal NTS infection; however, it was
not speciﬁed which genes were affected in these patients
(MacLennan et al., 2004). The protective role of these
cytokines against Salmonella appears to be independent of
the IFN-γ immune response (MacLennan et al., 2004). Rather,
it is suggested that the IL-23/Th17 pathway has a key role in
mucosal inﬂammatory responses to NTS infection (Godinez
et al., 2011).
Chronic mucocutaneous candidiasis (CMC)
Severe acquired immunodeﬁciencies (e.g., uncontrolled HIV
or Severe Combined Immunodeﬁciency) or genetic defects in
the IL-23/Th17 pathway can increase patients’ susceptibility
to a number of syndromes that are all associated with chronic
or recurrent mucosal or skin infections with Candida albicans
(Table 1; Puel et al., 2010b; Hanna and Etzioni, 2011;
Huppler et al., 2012). These syndromes are collectively
referred to as CMC (Hanna and Etzioni, 2011). CMC manifests
as superﬁcial lesions on the skin, nails, and mucosal surfaces
that often respond poorly to antifungal therapy (Puel et al.,
2010b; Hanna and Etzioni, 2011). Clinical presentations and
severities of CMC are variable, even between family members
with the same genetic mutations (Cárdenes et al., 2010;
Boisson-Dupuis et al., 2012; Lilic, 2012). Subtypes of CMC
include the autoimmune polyendocrinopathy-candidiasis-
ectodermal dystrophy syndrome (APECED), autosomal-
dominant CMC with or without thyroid disease, and isolated
CMC disease (van de Veerdonk et al., 2011). Across the
subtypes of CMC, IL-22 has been identiﬁed as a dominant
cytokine in providing protective immunity against candidiasis
(De Luca et al., 2010; Kisand et al., 2010). IL-17A and IL-17F
are also natural defenders against CMC, but studies have
suggested that these cytokines may be less critical compared
with IL-22 in mucosal host–defense mechanisms (De Luca
et al., 2010; Kisand et al., 2010 and 2011).
Another key modulator of human mucosal antifungal
defense is the β-glucan receptor, dectin-1. In a study of
family members affected by chronic vulvovaginal candidiasis
or onychomycosis, Ferwerda and colleagues identiﬁed stop-
codon mutations in dectin-1 that were associated with
reduced production of IL-17, tumor necrosis factor-α, and
IL-6 (Ferwerda et al., 2009). However, neutrophil function
is preserved in patients with dectin-1 deﬁciencies, resulting
in protection against invasive fungal infections (Ferwerda
et al., 2009).
Cytokine autoantibodies linked to APECED. APECED, also
known as autoimmune polyendocrinopathy syndrome type 1, is
a rare inherited disorder characterized by hypoparathyroidism,
adrenocortical failure (Addison’s disease), and severe CMC that is
localized to mucosal membranes (Kisand et al., 2011; Huppler
et al., 2012). Although almost all patients with APECED have
CMC, they rarely display increased susceptibility to other
infections (Puel et al., 2010b; Hanna and Etzioni, 2011;
Huppler et al., 2012; Puel et al., 2012). Autosomal-recessive
mutations in the autoimmune regulator (AIRE) gene result in high
levels of autoantibodies against IFN-α, IL-17F, IL-22 and to a
lesser extent IL-17A (Kisand et al., 2010; Puel et al., 2010a and b;
Huppler et al., 2012; Kluger et al., 2012).
Autosomal-dominant CMC with or without thyroid involvement.
Autosomal-dominant CMC has been observed in patients with
gain-of-function mutations in STAT1 (Liu et al., 2011; van de
Veerdonk et al., 2011; Boisson-Dupuis et al., 2012; Huppler
et al., 2012). These mutations increase STAT1-dependent cellular
responses to IFN-α/β, IFN-γ, and IL-27 and to cytokines that
predominantly activate STAT3. Increased STAT1 activation in
response to the STAT3-dependent IL-17 inducers IL-6 and IL-21
hinders development of T cells that produce IL-17A, IL-17F, and
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IL-22 (Liu et al., 2011; van de Veerdonk et al., 2011; Cypowyj
et al., 2012; Huppler et al., 2012). Several different STAT1 gain-
of-function missense mutations also have been identiﬁed, but
the link between the type of mutation and clinical presentation is
not well deﬁned. However, complete STAT1 deﬁciency is
thought to be associated with more severe infectious phenotypes
(Boisson-Dupuis et al., 2012).
Isolated CMC. Isolated CMC is commonly referred to as CMC
disease (Cypowyj et al., 2012). CMC disease without any other
known phenotype has been observed in patients with a complete
autosomal-recessive deﬁciency in the receptor IL-17RA (due to
mutations in the IL17RA gene) or autosomal-dominant mutations
in IL17F (Cypowyj et al., 2012; Puel et al., 2011). Genetic
mutations in IL-17RA result in a lack of cellular response to
IL-17A, IL-17F, IL-17A/IL-17F, IL-17C, and IL-17E (also known as
IL-25; Cypowyj et al., 2012; Puel et al., 2011).
Caspase recruitment domain-containing protein 9 (CARD9)
is a signal transducer found in the cytosol of myeloid cells
that is required for induction of Th17 cells (Huppler et al.,
2012; Drewniak et al., 2013). Isolated CMC has also been
observed in patients with autosomal-recessive CARD9
mutations. The CMC phenotype in CARD9-deﬁcient
patients tends to be more severe, and cases of invasive CNS
and brain candidiasis have been reported (Puel et al., 2010b;
Huppler et al., 2012; Drewniak et al., 2013; Sillevis Smitt and
Kuijpers, 2013; Wang et al., 2014). Some studies have
suggested that susceptibility to CMC in CARD9-deﬁcient
individuals results from impaired dectin-1 signaling
(Hanna and Etzioni, 2011). However, recent studies have
shown that neutrophil-killing defects may be responsible for
allowing more invasive forms of CMC to progress (Drewniak
et al., 2013).
Hyperimmunoglobulin E syndrome
The Hyperimmunoglobulin E syndrome (HIES, Job’s syn-
drome) is a rare primary immunodeﬁciency that can result in
severe atopic dermatitis, pneumatocele formation, connective
tissue and skeletal abnormalities, and recurrent skin and lung
infections (Hanna and Etzioni, 2011; Szczawinska-Poplonyk
et al., 2011). Cutaneous and pulmonary staphylococcal
infections and CMC are also observed in the majority of
patients with HIES (Puel et al., 2010b; Hanna and Etzioni,
2011). In addition, serum IgE levels are markedly elevated to
more than 10–100 times normal range (Ma et al., 2008;
Hanna and Etzioni, 2011).
Autosomal-dominant HIES is caused by dominant-negative
mutations in STAT3 (Ma et al., 2008; Zelante et al., 2009;
Hanna and Etzioni, 2011). These mutations result in decreased
expression of regulator retinoid-related orphan receptor γt,
which is a transcription factor required for IL-17 expression;
thus, IL-17A production is greatly reduced (Ma et al., 2008).
Reductions in IL-1β-, IL-6- IL-21-, and IL-23-induced differ-
entiation of naive CD4+ T cells into Th17 cells result in lower
Th17 cell counts and contribute to reductions in IL-17 and
IL-22 expression (Ma et al., 2008; Schimke et al., 2010;
Huppler et al., 2012; Puel et al., 2012). Different STAT3
mutations are associated with different levels of impairment in
IL-17 production and varying disease severity. For example,
IL-17 production was found to be completely absent in
patients with R382W or V463del STAT3 mutations, whereas
patients with STAT3 linker domain mutations produced
measureable amounts of IL-17 and had milder disease (van
de Veerdonk et al., 2010).
Another distinct disorder, autosomal-recessive HIES, has
been observed in patients with deﬁciencies in dedicator of
cytokinesis 8, which results in impaired T-cell activation and
memory (Schimke et al., 2010; Huppler et al., 2012; Lilic,
2012). In addition, dedicator of cytokinesis 8 regulates actin,
which may explain the skeletal abnormalities observed in
patients with HIES (Szczawinska-Poplonyk et al., 2011).
Isolated cases of autosomal-recessive HIES have also been
observed in patients with TYK2 deﬁciencies, suggesting that
defects in Janus kinase signaling may also be associated with
certain forms of HIES (Minegishi and Karasuyama, 2009;
Schimke et al., 2010; Lilic, 2012). Such deﬁciencies are
further upstream in the IL-23/Th17 pathway, as Janus kinases
phosphorylate STATs (Minegishi and Karasuyama, 2009). The
clinical features of autosomal-recessive HIES are similar to
autosomal-dominant HIES, but patients with the recessive
form may be more susceptible to severe fungal and viral
infections, as well as asthma, food allergies, and malignancies
(Szczawinska-Poplonyk et al., 2011; Huppler et al., 2012).
Patients with DOCK8 mutations are less likely to present with
certain cutaneous symptoms, such as newborn eczematous
eruptions, which are more common in patients with autosomal-
dominant HIES caused by STAT3 mutations (Sillevis Smitt and
Kuijpers, 2013).
DISCUSSION
Several diseases can manifest as a result of inherent or
acquired deﬁciencies in cytokines or their receptors. Exam-
ination of the clinical phenotypes from these diseases may
provide insights into potential side effects for therapies that
target these cytokines. Several important caveats should be
noted: importantly, anticytokine therapy is not expected to
mimic cytokine-signaling pathway mutations, in which the
development of these diseases is likely to be affected by
lifelong (and sometimes complete) depletion in cytokine
levels. Thus, the genetic diseases discussed herein are not
expected to mirror what would be observed during biologic
therapy for immune-mediated disorders. Furthermore, current
anticytokine therapy does not impair production of the
targeted cytokine and thus does not result in complete and,
more importantly, permanent loss of function. These distinc-
tions are critical because the extent of functional deﬁciencies
in rare diseases identiﬁed here corresponds to the extent of the
clinical phenotypes (van de Veerdonk et al., 2010). For example,
in patients with HIES, partial IL-17 deﬁciency is associated with
a milder clinical phenotype compared with complete IL-17
deﬁciency (van de Veerdonk et al., 2010). Similarly, in most of
the genetic disorders discussed, many different cytokines are
altered simultaneously and thus are highly dissimilar to single-
cytokine depletion mediated by a biologic.
Long-term favorable clinical outcomes are possible for
many patients with genetic deﬁciencies in the IL-23/Th17 pathway
because of redundancies in host–defense mechanisms and
A Blauvelt et al.
Deﬁciency Phenotypes in the IL-23/Th17 Pathway
1950 Journal of Investigative Dermatology (2015), Volume 135
because deﬁciencies in a single cytokine or its receptor
generally do not lead to widespread disease susceptibility
(Fieschi et al., 2003; Godinez et al., 2011). For example,
although early studies postulated that IL-12 production by
phagocytes and antigen-presenting cells was a key compo-
nent of both innate resistance and adaptive immune
responses (Trinchieri, 1995), Fieschi and colleagues later
found that deﬁciencies in IL-12 or its receptor do not increase
susceptibility to a wide range of infections (Fieschi and
Casanova, 2003; Fieschi et al., 2003). Instead, consequences
of these deﬁciencies are usually limited to MSMD, whereas
defenses against other microorganisms remain intact, and
risk for serious systemic infection remains low (Fieschi and
Casanova, 2003; Fieschi et al., 2003). Similarly, studies
examining susceptibility to NTS bacteremia have concluded
that, although IL-17A has a key role in protecting ileal
mucosa, isolated deﬁciencies in this cytokine are unlikely to
result in substantially increased risk for systemic Salmonella
infection because the antimicrobial functions of IL-17A, IL-1β,
and tumor necrosis factor-α are redundant such that all of
these cytokines can induce expression of neutrophil che-
moattractants in epithelial cells (Godinez et al., 2011). It is
more likely that broadly compromised host defenses are a
result of immunodeﬁciencies further upstream that affect
multiple inﬂammatory and immune response pathways.
Predictably, data suggest that deﬁciencies in cytokines and
receptors further downstream in the IL-23/Th17 pathway are
associated with fewer disorders than deﬁciencies in upstream
components of the pathway. For example, dysregulation of
IL12RB1, which encodes a common subunit of the IL-12 and
IL-23 receptor, is associated with increased susceptibility to a
range of infections, including MSMD, Salmonella, and
tuberculosis, whereas the potential consequences of more
downstream IL-17 deﬁciencies are generally limited to
superﬁcial skin and mucosal fungal infections. These obser-
vations are consistent with the involvement of upstream
cytokines in pleotropic processes, including the regulation of
other cytokines, whereas downstream cytokines are generally
effectors of speciﬁc target tissue responses. Deﬁciencies in
signaling pathways used by several cytokines also tend to be
associated with a higher number of associated disorders. As
shown in Figure 1b, upstream cytokines are more broadly
involved in defense mechanisms against a range of bacterial,
fungal, and opportunistic infections compared with down-
stream cytokines (Bustamante et al., 2008; Di Cesare et al.,
2009; Furst, 2010; Chu, 2013). In contrast, human deﬁ-
ciencies in receptors for downstream cytokines, most notably
in the IL-17 family (IL-17A through F), tend to manifest as
increased susceptibility to a few speciﬁc types of infection,
including mucocutaneous candidiasis and cutaneous Staphy-
lococcal infections alone (Gaffen, 2011; Cypowyj et al., 2012;
Patel et al., 2013). The role of IL-17 cytokines in host defense
against most other common pathogens is largely redundant;
for example, both IL-17A and IL-17F are needed for muco-
cutaneous immunity against C. albicans (Girolomoni et al.,
2012; van den Berg and McInnes, 2013), and no mutations in
IL-17A resulting in generalized immunodeﬁciency have been
identiﬁed to date (Cypowyj et al., 2012; Patel et al., 2013).
Overall, this paper has explored how patients inherently
deﬁcient in certain components of the IL-23/Th17 pathway
may—and may not—be analogous to patients receiving
agents that are also designed to target this pathway. Under-
standing the consequences of this inhibition may thus inform
future long-term collection and analyses of data related to
potential infectious complications of these agents.
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